Synlett 2016; 27(11): 1607-1612
DOI: 10.1055/s-0035-1561440
synpacts
© Georg Thieme Verlag Stuttgart · New York

Combined Chemo-Anti-Inflammatory Prodrugs and Nanoparticles

Rakesh K. Pathak, Shanta Dhar*
  • NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA   eMail: shanta@uga.edu
Weitere Informationen

Publikationsverlauf

Received: 05. Januar 2016

Accepted after revision: 21. März 2016

Publikationsdatum:
22.April 2016 (eFirst)

Abstract

Combining multiple drugs in one platform has the ability to override the limitations of singly administered therapeutic and may provide potential alternative treatment options for aggressive prostate cancer resistant to conventional chemotherapy. For in vivo applications, combination therapeutics should be engineered to include nanoparticles for efficacious delivery. Here, we discuss the aspects of combining chemotherapy with anti-inflammatory drugs for metastatic castration resistant prostate cancer. We highlight the concept of combining cisplatin and Aspirin in a single platinum(IV) prodrug for efficacious in vitro biological actions. These two drugs were further incorporated in an engineered biodegradable polymer, which can self-assemble in the presence of a block copolymer to controlled-release nanoparticles to deliver multiple therapeutics in a predefined ratio.

1 Introduction

2 Chemo-Anti-inflammatory Approaches for Chemo-Resistant Prostate Cancer: Challenges and Opportunities

3 Chemo-Anti-inflammatory Platinum(IV) Prodrugs

4 Polymeric Nanoparticle for Co-delivery of Cisplatin and Aspirin

5 Future Perspectives

 
  • References

  • 1 Sfanos KS, De Marzo AM. Histopathology 2012; 60: 199
  • 2 Quail DF, Joyce JA. Nat. Med. 2013; 19: 1423
  • 3 de Groot DJ. A, de Vries EG. E, Groen HJ. M, de Jong S. Crit. Rev. Oncol. Hemat. 2007; 61: 52
  • 4 Dong H, Liu G, Jiang B, Guo J, Tao G, Yiu WE. I, Zhou J, Li G. Biomed. Rep. 2014; 2: 344
  • 5 Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. Nat. Rev. Drug Discovery 2008; 7: 255
  • 6 Singh Y, Palombo M, Sinko PJ. Curr. Med. Chem. 2008; 15: 1802
  • 7 Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Nat. Rev. Drug Discovery 2009; 8: 111
  • 8 Huttunen KM, Raunio H, Rautio J. Pharmacol. Rev. 2011; 63: 750
  • 9 Yang Y.-H, Aloysius H, Inoyama D, Chen Y, Hu L.-Q. Acta. Pharm. Sin. B 2011; 1: 143
  • 10 Rosenberg B, Van Camp L, Krigas T. Nature (London, U.K.) 1965; 205: 698
  • 11 Dasari S, Tchounwou PB. Eur. J. Pharmacol. 2014; 740: 364
  • 12 Rosenberg B, VanCamp L. Cancer Res. 1970; 30: 1799
  • 13 Zorbas-Seifried S, Jakupec MA, Kukushkin NV, Groessl M, Hartinger CG, Semenova O, Zorbas H, Kukushkin VY, Keppler BK. Mol. Pharmacol. 2007; 71: 357
  • 14 White JD, Haley MM, DeRose VJ. Acc. Chem. Res. 2016; 49: 56
  • 15 Wilson JJ, Lippard SJ. Chem. Rev. 2014; 114: 4470
  • 16 Shi Y, Liu S.-A, Kerwood DJ, Goodisman J, Dabrowiak JC. J. Inorg. Biochem. 2012; 107: 6
  • 17 Wexselblatt E, Gibson D. J. Inorg. Biochem. 2012; 117: 220
  • 18 Hall MD, Mellor HR, Callaghan R, Hambley TW. J. Med. Chem. 2007; 50: 3403
  • 19 Rayburn ER, Ezell SJ, Zhang R. Mol. Cell Pharmacol. 2009; 1: 29
  • 20 Ricciotti E, FitzGerald GA. Arterioscler., Thromb., Vasc. Biol. 2011; 31: 986
  • 21 Greenhough A, Smartt HJ. M, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. Carcinogenesis 2009; 30: 377
  • 22 Alfonso L, Ai G, Spitale RC, Bhat GJ. Br. J. Cancer 2014; 111: 61
  • 23 Rybak LP, Ramkumar V. Kidney Int. 2007; 72: 931
  • 24 Choudhury D, Ahmed Z. Nat. Clin. Pract. Neph. 2006; 2: 80
  • 25 Pathak RK, Marrache S, Choi JH, Berding TB, Dhar S. Angew. Chem. Int. Ed. 2014; 53: 1963
  • 26 Pathak RK, Dhar S. J. Am. Chem. Soc. 2015; 137: 8324
  • 27 Siegel RL, Miller KD, Jemal A. CA Cancer J. Clin. 2015; 65: 5
  • 28 Pavuk M, Michalek JE, Ketchum NS. J. Expos. Sci. Environ. Epidemiol. 2005; 16: 184
  • 29 Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, Kelley MJ. Mil. Med. 2012; 177: 693
  • 30 Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Nat. Clin. Pract. Urol. 2009; 6: 76
  • 31 Datta K, Muders M, Zhang H, Tindall DJ. Future Oncol. 2010; 6: 823
  • 32 Merseburger AS, Haas GP, von Klot C.-A. Ther. Adv. Urol. 2015; 7: 9
  • 33 Abidi A. J. Pharmacol. Pharmacother. 2013; 4: 230
  • 34 Mitragotri S, Burke PA, Langer R. Nat. Rev. Drug Discov. 2014; 13: 655
  • 35 Cheng Q, Shi H, Wang H, Min Y, Wang J, Liu Y. Chem. Commun. 2014; 50: 7427
  • 36 Cheng Q, Shi H, Huang H, Cao Z, Wang J, Liu Y. Chem. Commun. 2015; 51: 17536
  • 37 Neumann W, Crews BC, Sárosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E. ChemMedChem 2015; 10: 183
  • 38 Johnstone TC, Lippard SJ. Inorg. Chem. 2013; 52: 9915
  • 39 Sinisi M, Intini FP, Natile G. Inorg. Chem. 2012; 51: 9694
  • 40 Wexselblatt E, Yavin E, Gibson D. Angew. Chem. Int. Ed. 2013; 52: 6059
  • 41 Marrache S, Pathak RK, Dhar S. Proc. Natl. Acad. Sci. U.S.A. 2014; 111: 10444
  • 42 Kalathil AA, Kumar A, Banik B, Ruiter TA, Pathak RK, Dhar S. Chem. Commun. 2016; 52: 140
  • 43 Feldhaeusser B, Platt SR, Marrache S, Kolishetti N, Pathak RK, Montgomery DJ, Reno LR, Howerth E, Dhar S. Nanoscale 2015; 7: 13822